cnsp

CNS Pharmaceuticals Development Partner, WPD Pharmaceuticals, Reports Active Compound in Licensed Drug Candidate Reduces COVID19 Replication in Vitro by 100%

CNS Pharmaceuticals Development Partner, WPD Pharmaceuticals, Reports Active Compound in Licensed Drug Candidate Reduces COVID19 Replication in Vitro by 100%

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) in collaboration with its development partner WPD Pharmaceuticals Inc. intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the co..